{"id":"https://openalex.org/W1975685996","doi":"https://doi.org/10.1158/0008-5472.sabcs11-s3-4","title":"S3-4: ER Downregulation with Fulvestrant in Combination with pan-PI3K Inhibitor BKM120 Synergizes Against ER+/PI3K-Mutant Breast Cancer Xenografts In Vivo.","display_name":"S3-4: ER Downregulation with Fulvestrant in Combination with pan-PI3K Inhibitor BKM120 Synergizes Against ER+/PI3K-Mutant Breast Cancer Xenografts In Vivo.","publication_year":2011,"publication_date":"2011-12-01","ids":{"openalex":"https://openalex.org/W1975685996","doi":"https://doi.org/10.1158/0008-5472.sabcs11-s3-4","mag":"1975685996"},"language":"en","primary_location":{"id":"doi:10.1158/0008-5472.sabcs11-s3-4","doi":"https://doi.org/10.1158/0008-5472.sabcs11-s3-4","is_oa":false,"landing_page_url":"https://doi.org/10.1158/0008-5472.sabcs11-s3-4","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5112258739","display_name":"TW Miller","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH","US"],"is_corresponding":false,"raw_author_name":"TW Miller","raw_affiliation_strings":["1Vanderbilt University, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Novartis Inst. for Biomedical Research, Basel, Switzerland","Novartis Inst. for Biomedical Research, Basel, Switzerland","Vanderbilt University, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Vanderbilt University, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Novartis Inst. for Biomedical Research, Basel, Switzerland","institution_ids":["https://openalex.org/I200719446","https://openalex.org/I4210117453","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Novartis Inst. for Biomedical Research, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Vanderbilt University, Nashville, TN","institution_ids":["https://openalex.org/I200719446"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048586707","display_name":"EM Fox","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH","US"],"is_corresponding":false,"raw_author_name":"EM Fox","raw_affiliation_strings":["1Vanderbilt University, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Novartis Inst. for Biomedical Research, Basel, Switzerland","Novartis Inst. for Biomedical Research, Basel, Switzerland","Vanderbilt University, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Vanderbilt University, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Novartis Inst. for Biomedical Research, Basel, Switzerland","institution_ids":["https://openalex.org/I200719446","https://openalex.org/I4210117453","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Novartis Inst. for Biomedical Research, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Vanderbilt University, Nashville, TN","institution_ids":["https://openalex.org/I200719446"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089113899","display_name":"Justin Micah Balko","orcid":"https://orcid.org/0000-0002-4263-5974","observed_orcids":["https://orcid.org/0000-0002-4263-5974"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH","US"],"is_corresponding":false,"raw_author_name":"JM Balko","raw_affiliation_strings":["1Vanderbilt University, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Novartis Inst. for Biomedical Research, Basel, Switzerland","Novartis Inst. for Biomedical Research, Basel, Switzerland","Vanderbilt University, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Vanderbilt University, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Novartis Inst. for Biomedical Research, Basel, Switzerland","institution_ids":["https://openalex.org/I200719446","https://openalex.org/I4210117453","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Novartis Inst. for Biomedical Research, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Vanderbilt University, Nashville, TN","institution_ids":["https://openalex.org/I200719446"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017781933","display_name":"IM Meszoely","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH","US"],"is_corresponding":false,"raw_author_name":"IM Meszoely","raw_affiliation_strings":["1Vanderbilt University, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Novartis Inst. for Biomedical Research, Basel, Switzerland","Novartis Inst. for Biomedical Research, Basel, Switzerland","Vanderbilt University, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Vanderbilt University, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Novartis Inst. for Biomedical Research, Basel, Switzerland","institution_ids":["https://openalex.org/I200719446","https://openalex.org/I4210117453","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Novartis Inst. for Biomedical Research, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Vanderbilt University, Nashville, TN","institution_ids":["https://openalex.org/I200719446"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110139251","display_name":"ME Sanders","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH","US"],"is_corresponding":false,"raw_author_name":"ME Sanders","raw_affiliation_strings":["1Vanderbilt University, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Novartis Inst. for Biomedical Research, Basel, Switzerland","Novartis Inst. for Biomedical Research, Basel, Switzerland","Vanderbilt University, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Vanderbilt University, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Novartis Inst. for Biomedical Research, Basel, Switzerland","institution_ids":["https://openalex.org/I200719446","https://openalex.org/I4210117453","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Novartis Inst. for Biomedical Research, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Vanderbilt University, Nashville, TN","institution_ids":["https://openalex.org/I200719446"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041766594","display_name":"MG Kuba","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH","US"],"is_corresponding":false,"raw_author_name":"MG Kuba","raw_affiliation_strings":["1Vanderbilt University, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Novartis Inst. for Biomedical Research, Basel, Switzerland","Novartis Inst. for Biomedical Research, Basel, Switzerland","Vanderbilt University, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Vanderbilt University, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Novartis Inst. for Biomedical Research, Basel, Switzerland","institution_ids":["https://openalex.org/I200719446","https://openalex.org/I4210117453","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Novartis Inst. for Biomedical Research, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Vanderbilt University, Nashville, TN","institution_ids":["https://openalex.org/I200719446"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068721624","display_name":"Nikhil Wagle","orcid":"https://orcid.org/0000-0003-3332-9438","observed_orcids":["https://orcid.org/0000-0003-3332-9438"]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH","US"],"is_corresponding":false,"raw_author_name":"N Wagle","raw_affiliation_strings":["1Vanderbilt University, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Novartis Inst. for Biomedical Research, Basel, Switzerland","Novartis Inst. for Biomedical Research, Basel, Switzerland","Vanderbilt University, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Vanderbilt University, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Novartis Inst. for Biomedical Research, Basel, Switzerland","institution_ids":["https://openalex.org/I200719446","https://openalex.org/I4210117453","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Novartis Inst. for Biomedical Research, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Vanderbilt University, Nashville, TN","institution_ids":["https://openalex.org/I200719446"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000715365","display_name":"LA Garraway","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH","US"],"is_corresponding":false,"raw_author_name":"LA Garraway","raw_affiliation_strings":["1Vanderbilt University, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Novartis Inst. for Biomedical Research, Basel, Switzerland","Novartis Inst. for Biomedical Research, Basel, Switzerland","Vanderbilt University, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Vanderbilt University, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Novartis Inst. for Biomedical Research, Basel, Switzerland","institution_ids":["https://openalex.org/I200719446","https://openalex.org/I4210117453","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Novartis Inst. for Biomedical Research, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Vanderbilt University, Nashville, TN","institution_ids":["https://openalex.org/I200719446"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043694752","display_name":"S-M Maira","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH","US"],"is_corresponding":false,"raw_author_name":"S-M Maira","raw_affiliation_strings":["1Vanderbilt University, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Novartis Inst. for Biomedical Research, Basel, Switzerland","Novartis Inst. for Biomedical Research, Basel, Switzerland","Vanderbilt University, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Vanderbilt University, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Novartis Inst. for Biomedical Research, Basel, Switzerland","institution_ids":["https://openalex.org/I200719446","https://openalex.org/I4210117453","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Novartis Inst. for Biomedical Research, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Vanderbilt University, Nashville, TN","institution_ids":["https://openalex.org/I200719446"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5012305640","display_name":"CL Arteaga","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1283582996","display_name":"Novartis (Switzerland)","ror":"https://ror.org/02f9zrr09","country_code":"CH","type":"company","lineage":["https://openalex.org/I1283582996"]},{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]},{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH","US"],"is_corresponding":false,"raw_author_name":"CL Arteaga","raw_affiliation_strings":["1Vanderbilt University, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Novartis Inst. for Biomedical Research, Basel, Switzerland","Novartis Inst. for Biomedical Research, Basel, Switzerland","Vanderbilt University, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Vanderbilt University, Nashville, TN; Dana-Farber Cancer Institute, Boston, MA; Novartis Inst. for Biomedical Research, Basel, Switzerland","institution_ids":["https://openalex.org/I200719446","https://openalex.org/I4210117453","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Novartis Inst. for Biomedical Research, Basel, Switzerland","institution_ids":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]},{"raw_affiliation_string":"Vanderbilt University, Nashville, TN","institution_ids":["https://openalex.org/I200719446"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.12429162,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"71","issue":"24_Supplement","first_page":"S3","last_page":"4"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.6577000021934509,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.6577000021934509,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.2515000104904175,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10756","display_name":"Estrogen and related hormone effects","score":0.05849999934434891,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/estrogen-receptor-positive-breast-cancer","display_name":"estrogen receptor-positive breast cancer","score":0.8410000205039978},{"id":"https://openalex.org/keywords/pik3ca-mutation","display_name":"PIK3CA mutation","score":0.8100000023841858},{"id":"https://openalex.org/keywords/aromatase-inhibitor-resistance","display_name":"aromatase inhibitor resistance","score":0.8370000123977661},{"id":"https://openalex.org/keywords/estrogen-deprivation","display_name":"estrogen deprivation","score":0.6669999957084656},{"id":"https://openalex.org/keywords/fulvestrant","display_name":"fulvestrant","score":0.8140000104904175},{"id":"https://openalex.org/keywords/bkm120","display_name":"BKM120","score":0.9490000009536743},{"id":"https://openalex.org/keywords/pan-pi3k-inhibitor","display_name":"pan-PI3K inhibitor","score":0.9350000023841858},{"id":"https://openalex.org/keywords/bez235","display_name":"BEZ235","score":0.9369999766349792},{"id":"https://openalex.org/keywords/ki-67-proliferation-index","display_name":"Ki-67 proliferation index","score":0.7239999771118164}],"concepts":[{"id":"https://openalex.org/C2780482068","wikidata":"https://www.wikidata.org/wiki/Q5508491","display_name":"Fulvestrant","level":5,"score":0.8549260497093201},{"id":"https://openalex.org/C2778812593","wikidata":"https://www.wikidata.org/wiki/Q194974","display_name":"Letrozole","level":5,"score":0.8056474924087524},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.6979234218597412},{"id":"https://openalex.org/C2778504769","wikidata":"https://www.wikidata.org/wiki/Q3040305","display_name":"Aromatase inhibitor","level":5,"score":0.6542286276817322},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6062580943107605},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.5866588354110718},{"id":"https://openalex.org/C84606932","wikidata":"https://www.wikidata.org/wiki/Q416496","display_name":"Estrogen receptor","level":4,"score":0.4805586636066437},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4721039831638336},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4606698751449585},{"id":"https://openalex.org/C2777164284","wikidata":"https://www.wikidata.org/wiki/Q277954","display_name":"Estrogen","level":2,"score":0.46066370606422424},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4588404893875122},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.4532526433467865},{"id":"https://openalex.org/C2776166826","wikidata":"https://www.wikidata.org/wiki/Q415287","display_name":"Aromatase","level":4,"score":0.4167519211769104},{"id":"https://openalex.org/C2779744173","wikidata":"https://www.wikidata.org/wiki/Q15269707","display_name":"Palbociclib","level":5,"score":0.4143088459968567},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.35070711374282837},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3460443615913391},{"id":"https://openalex.org/C2775930923","wikidata":"https://www.wikidata.org/wiki/Q12859063","display_name":"Metastatic breast cancer","level":4,"score":0.2629837691783905},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.1512896716594696},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.06878295540809631}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/0008-5472.sabcs11-s3-4","doi":"https://doi.org/10.1158/0008-5472.sabcs11-s3-4","is_oa":false,"landing_page_url":"https://doi.org/10.1158/0008-5472.sabcs11-s3-4","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2083197632","https://openalex.org/W2168485476","https://openalex.org/W2523546815","https://openalex.org/W2319399724","https://openalex.org/W2023113466","https://openalex.org/W2030179432","https://openalex.org/W2887531203","https://openalex.org/W2018846584","https://openalex.org/W2102004296","https://openalex.org/W2164620725"],"abstract_inverted_index":{"Abstract":[0],"ER+":[1,132,343],"breast":[2,33,133,162,344,427],"cancers":[3],"typically":[4],"respond":[5],"to":[6,25,83,144,172,176,235,252,281,292,328,337],"aromatase":[7,422],"inhibitors":[8],"(AIs),":[9],"but":[10],"a":[11,73,150,227,432,439],"significant":[12],"fraction":[13],"exhibit":[14],"de":[15],"novo":[16],"or":[17,80,97,265,355],"acquired":[18],"resistance.":[19],"To":[20],"discover":[21],"mechanisms":[22],"of":[23,85,110,124,131,189,207,247,261,278,297,341,361,368,406,412,434],"resistance":[24,291],"AIs,":[26],"we":[27],"maintained":[28],"four":[29],"ER+,":[30],"hormone-dependent":[31],"human":[32],"cancer":[34,163,345,428],"cell":[35,62,104,258,346,408],"lines":[36,347],"in":[37,115,128,149,197,204,231,305,325,348,357,386,393],"hormone-depleted":[38],"conditions":[39],"for":[40,168],"several":[41],"months":[42],"until":[43],"estrogen-independent":[44,268],"populations":[45],"emerged":[46],"(termed":[47],"long-term":[48],"estrogen-deprived,":[49],"LTED).":[50],"A":[51],"siRNA":[52,266],"kinome":[53],"screen":[54],"identified":[55],"42":[56,87],"kinases":[57],"that":[58,244,271,287,318,397,417],"suppressed":[59,102],"hormone-independent":[60,111],"MCF-7/LTED":[61],"growth":[63,340,367],"\u226533%":[64],"(p<0.05).":[65],"Pathway":[66],"analysis":[67,380],"revealed":[68],"phosphatidylinositol":[69],"3-kinase":[70],"(PI3K)":[71],"as":[72],"central":[74],"hub":[75],"which":[76],"integrates":[77],"signaling":[78,82,299],"from,":[79],"emits":[81],"many":[84],"these":[86],"kinases.":[88],"Further,":[89],"treatment":[90,184],"with":[91,147,157,166,237,263,311,332,335,352,425],"the":[92,98,108,117,120,141,187,208,250,272,339,366,373,398],"PI3K/mTOR":[93],"dual":[94],"inhibitor":[95,100],"BEZ235":[96],"pan-PI3K":[99],"BKM120":[101,333,356],"LTED":[103,257,306],"growth,":[105,269],"and":[106,185,199,308,320,389,410,438],"prevented":[107],"emergence":[109],"cells.":[112],"Activating":[113],"mutations":[114,139],"PIK3CA,":[116],"gene":[118],"encoding":[119],"p110\u03b1":[121],"catalytic":[122],"subunit":[123],"PI3K,":[125],"are":[126],"present":[127],"about":[129],"35%":[130],"cancers.":[134],"We":[135],"investigated":[136],"whether":[137],"PIK3CA":[138,218,239],"modify":[140],"tumor":[142,179,377,401,407],"response":[143,251],"estrogen":[145,253,282,293,329,362],"deprivation":[146],"letrozole":[148,167],"pre-surgical":[151],"clinical":[152],"trial":[153],"(NCT00651976).":[154],"Twenty-one":[155],"patients":[156,424],"stage":[158],"I-II":[159],"operable":[160],"ER+/HER2\u2212":[161],"were":[164,181],"treated":[165],"10\u201321":[169],"days":[170],"up":[171],"24":[173],"h":[174],"prior":[175],"surgery.":[177],"Core":[178],"biopsies":[180],"obtained":[182],"before":[183],"at":[186],"time":[188],"surgical":[190],"resection.":[191],"Ki67":[192,209,232],"immunohistochemistry":[193],"(IHC)":[194],"was":[195,215],"scored":[196],"pre-":[198],"post-letrozole":[200],"specimens.":[201],"The":[202],"change":[203],"natural":[205],"log":[206],"score":[210,233],"between":[211],"pre-and":[212],"post-treatment":[213],"samples":[214],"stratified":[216],"by":[217,403],"mutant":[219],"vs.":[220],"wildtype":[221],"(WT)":[222],"status.":[223],"PIK3CA-mutant":[224],"tumors":[225,236,388],"exhibited":[226],"statistically":[228],"lower":[229],"reduction":[230],"compared":[234],"WT":[238],"(p=0.03).":[240],"These":[241,414],"findings":[242],"suggest":[243,416],"mutational":[245],"activation":[246],"PI3K":[248,319,440],"attenuates":[249],"deprivation.":[254,283,294,330],"In":[255],"some":[256],"lines,":[259],"downregulation":[260,310],"ER":[262,274,309,321,436],"fulvestrant":[264,312,336,354],"inhibited":[267,365],"suggesting":[270,317],"unliganded":[273],"can":[275],"maintain":[276],"proliferation":[277,409],"cells":[279,326,385,392],"adapted":[280,327],"Prior":[284],"work":[285],"suggested":[286],"PI3K-ER":[288],"crosstalk":[289],"promotes":[290],"However,":[295],"inhibition":[296,405],"PI3K/AKT/TORC1":[298],"did":[300,313],"not":[301,314],"alter":[302],"ERS167":[303],"phosphorylation":[304],"cells,":[307],"inhibit":[315,338],"PI3K/AKT,":[316],"modulate":[322],"non-overlapping":[323],"pathways":[324],"Treatment":[331,351],"synergized":[334],"6/8":[342],"estrogen-depleted":[349],"conditions.":[350],"single-agent":[353],"athymic":[358],"mice":[359],"devoid":[360],"supplementation":[363],"partially":[364],"ER+/PI3K-mutant":[369,426],"MCF-7":[370],"xenografts,":[371],"while":[372],"combination":[374,399,433],"induced":[375,400],"near-complete":[376],"regression.":[378],"IHC":[379],"showed":[381],"increased":[382],"cleaved":[383],"caspase-3+":[384],"BKM120-treated":[387],"decreased":[390],"Ki67+":[391],"fulvestrant-treated":[394],"tumors,":[395],"implying":[396],"regression":[402],"both":[404],"induction":[411],"apoptosis.":[413],"data":[415],"upon":[418],"progression":[419],"on":[420],"an":[421,435],"inhibitor,":[423],"would":[429],"benefit":[430],"from":[431],"downregulator":[437],"pathway":[441],"inhibitor.":[442],"Citation":[443],"Information:":[444],"Cancer":[445],"Res":[446],"2011;71(24":[447],"Suppl):Abstract":[448],"nr":[449],"S3-4.":[450]},"counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2016-06-24T00:00:00"}